Of note, tetrabenazine and deutetrabenazine, which have been approved by the U.S. Food and Drug Administration (FDA) to manage HD symptoms (mainly chorea), act as inhibitors of the vesicular monoamine transporter 2 (VMAT2), decreasing monoamine release in the synaptic cleft [21,22]. This evidence concerns the gene SLC18A2 and Chorea.